Women in England with breast cancer may qualify for drug that buys ‘precious’ time
by Andrew Gregory Health editor from Science | The Guardian on (#5ZM13)
Nice approves Keytruda, which with chemotherapy can lengthen survival of women with triple negative breast cancer
Women with advanced breast cancer in England will be able to benefit from a new type of immunotherapy on the NHS after a U-turn by the medicines watchdog.
The National Institute for Health and Care Excellence (Nice) has overturned its draft rejection of Keytruda (pembrolizumab) and said women in England can take the drug in combination with chemotherapy.
Continue reading...